 |
Mission
GangaGen, Inc. is a biotechnology company focused on the development of
proprietary products for the prevention and treatment of bacterial infections,
particularly infections that are resistant to antibiotics, through the
application of contemporary molecular and clinical sciences. The Company's
technology has arisen from its studies of bacteriophage, nature’s antibiotics.
|
|
GangaGen's
unique business strategy is to maximize efficiency
through cost-effective R & D operations in
Bangalore, India, pursuing the treatment of
commercially significant infections that require
the most straightforward and least expensive
clinical trials.
|
 |
|
 |
Company
Overview
GangaGen
Inc was initially formed September 23, 2000 by
CEO and founder Dr. J. Ramachandran in Bangalore,
India, as GangaGen Biotechnologies Pvt Ltd (GBPL)
to develop novel therapies for treating
antibiotic-resistant infection. Based on the
emerging opportunities for treating bacterial
infection in the medical, veterinary,
agricultural and environmental settings
globally, and the interest of investors in the
U.S. and Canada, GangaGen Inc was incorporated
as a Delaware Corporation in August 2001.
|
|
|
GangaGen
Inc. received permission from the Ministry of Commerce
& Industry, Govt. of India on December 21, 2001 to
convert GBPL into a fully owned subsidiary of GangaGen
Inc.
|
|
The
long-term objective of the Company is to commercially develop products to
control multiple species of bacteria pathogenic to humans, particularly
antibiotic-resistant strains, based on its knowledge of bacteriophage.
GangaGen's business strategy is to pursue specific human, initially
topical, applications where there is an opportunity to shorten the long
product development timeline by focusing on those indications that require
shorter clinical trials and enable faster regulatory approval.
|
 |
|
|
The
company’s lead product is a recombinant protein,
P128, that binds to and kills Staphylococcus,
including methicillin-resistant strains of S.
aureus (MRSA). This product is in late
preclinical development.
|
|
The
second human topical application the Company is pursuing is the control of
Pseudomonas aeruginosa in burns & wounds. The product is also
expected to be valuable in
treating P. aeruginosa
infections in the lungs of patients with cystic fibrosis. The Company
intends to pursue these with strategic partners.
|
 |
|
|
TOP
|
|
|
;)
;)
;)
;)
;)
;)